

PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



TRAF2 (T117) Peptide

Cat No.: AP0698P

Background

Tumor necrosis factor (TNF)-activated cell signaling is mediated primarily through the TNF receptor 1 (TNF-R1) and, to a lesser extent, TNF-R2. Both TNF receptors are members of the expanding TNF receptor superfamily, which includes the FAS antigen and CD40. Potential insight into an understanding of TNF receptor-mediated signaling was provided by the identification of two related proteins, TRAF1 and TRAF2 (for TNF receptor-associated factors 1 and 2, respectively). Both function to form heterodimeric complexes and associate with the cytoplasmic domain of TNF-R2. A third member of this protein family, alternatively designated CD40 bp, CRAF1, LAP1 or TRAF3, has been identified and shown to associate with the cytoplasmic domain of CD40. The similarity between a specific region of TRAF3 with regions of TRAF1 and TRAF2 define a "TRAF-C" domain that is necessary and sufficient for CD40 binding and homodimerization.

Swiss-Prot

Q12933

Applications

Blocking

Specificity

This peptide can be used with studies using AP0698 TRAF2 (T117) pAb.

Purification & Purity

Synthetic peptide TRAF2 (T117). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.

Bioworld Technology, Inc.

1660 South Highway 100, Suite 500 St. Louis Park, MN
55416, USA.

Email: info@bioworlde.com

Tel: 6123263284

Fax: 6122933841

Bioworld technology, co, Ltd.

No 9, weidi road Qixia District Nanjing, 210046,
P, R.China.

Email: info@biogot.com

Tel: +86-025-68037686 Fax: +86-025-68035151